2018-2023 Global Epigenetics Drugs and Diagnostic Technologies Consumption Market Report

August 2018 | 179 pages | ID: 2DBA678B73CEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Epigenetics Drugs and Diagnostic Technologies market for 2018-2023.

The drugs and technologies that treat the reletive diseases
Rising incidence of gene expression changes due to chemical modifications in DNA or chromatin is the major factor driving the growth of epigenetics drugs and diagnostic technologies market
Increasing demand for epigenetics drugs and diagnostic technology is a direct consequence of rapidly increasing incidences of oncological disorders
Over the next five years, LPI(LP Information) projects that Epigenetics Drugs and Diagnostic Technologies will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Epigenetics Drugs and Diagnostic Technologies market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• HDAC inhibitors
• DNMT inhibitors

Segmentation by application:

• Non coding RNA’s
• Micro RNA’s
• Histone modifications
• DNA methylation

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Varlix Plc
• Topotarget
• Syndax Pharmaceuticals
• Spectrum Pharmaceuticals
• Promega
• Novartis
• Oncolys BioPharma
• MDxHealth
• Merck
• Illumina
• Epizyme
• Forum Pharmaceuticals
• EpiGentek
• Chroma Therapeutics
• Celleron Therapeutics
• CellCentric
• Astex Pharmaceuticals
• Acetylon Pharmaceuticals
• 4SC AG
• Eisai
• Pharmacyclics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Epigenetics Drugs and Diagnostic Technologies consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Epigenetics Drugs and Diagnostic Technologies market by identifying its various subsegments.
• Focuses on the key global Epigenetics Drugs and Diagnostic Technologies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Epigenetics Drugs and Diagnostic Technologies with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Epigenetics Drugs and Diagnostic Technologies submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Epigenetics Drugs and Diagnostic Technologies Consumption 2013-2023
  2.1.2 Epigenetics Drugs and Diagnostic Technologies Consumption CAGR by Region
2.2 Epigenetics Drugs and Diagnostic Technologies Segment by Type
  2.2.1 HDAC inhibitors
  2.2.2 DNMT inhibitors
2.3 Epigenetics Drugs and Diagnostic Technologies Consumption by Type
  2.3.1 Global Epigenetics Drugs and Diagnostic Technologies Consumption Market Share by Type (2013-2018)
  2.3.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Epigenetics Drugs and Diagnostic Technologies Sale Price by Type (2013-2018)
2.4 Epigenetics Drugs and Diagnostic Technologies Segment by Application
  2.4.1 Non coding RNA’s
  2.4.2 Micro RNA’s
  2.4.3 Histone modifications
  2.4.4 DNA methylation
2.5 Epigenetics Drugs and Diagnostic Technologies Consumption by Application
  2.5.1 Global Epigenetics Drugs and Diagnostic Technologies Consumption Market Share by Application (2013-2018)
  2.5.2 Global Epigenetics Drugs and Diagnostic Technologies Value and Market Share by Application (2013-2018)
  2.5.3 Global Epigenetics Drugs and Diagnostic Technologies Sale Price by Application (2013-2018)

3 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES BY PLAYERS

3.1 Global Epigenetics Drugs and Diagnostic Technologies Sales Market Share by Players
  3.1.1 Global Epigenetics Drugs and Diagnostic Technologies Sales by Players (2016-2018)
  3.1.2 Global Epigenetics Drugs and Diagnostic Technologies Sales Market Share by Players (2016-2018)
3.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue Market Share by Players
  3.2.1 Global Epigenetics Drugs and Diagnostic Technologies Revenue by Players (2016-2018)
  3.2.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue Market Share by Players (2016-2018)
3.3 Global Epigenetics Drugs and Diagnostic Technologies Sale Price by Players
3.4 Global Epigenetics Drugs and Diagnostic Technologies Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Epigenetics Drugs and Diagnostic Technologies Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Epigenetics Drugs and Diagnostic Technologies Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES BY REGIONS

4.1 Epigenetics Drugs and Diagnostic Technologies by Regions
  4.1.1 Global Epigenetics Drugs and Diagnostic Technologies Consumption by Regions
  4.1.2 Global Epigenetics Drugs and Diagnostic Technologies Value by Regions
4.2 Americas Epigenetics Drugs and Diagnostic Technologies Consumption Growth
4.3 APAC Epigenetics Drugs and Diagnostic Technologies Consumption Growth
4.4 Europe Epigenetics Drugs and Diagnostic Technologies Consumption Growth
4.5 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Consumption Growth

5 AMERICAS

5.1 Americas Epigenetics Drugs and Diagnostic Technologies Consumption by Countries
  5.1.1 Americas Epigenetics Drugs and Diagnostic Technologies Consumption by Countries (2013-2018)
  5.1.2 Americas Epigenetics Drugs and Diagnostic Technologies Value by Countries (2013-2018)
5.2 Americas Epigenetics Drugs and Diagnostic Technologies Consumption by Type
5.3 Americas Epigenetics Drugs and Diagnostic Technologies Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Epigenetics Drugs and Diagnostic Technologies Consumption by Countries
  6.1.1 APAC Epigenetics Drugs and Diagnostic Technologies Consumption by Countries (2013-2018)
  6.1.2 APAC Epigenetics Drugs and Diagnostic Technologies Value by Countries (2013-2018)
6.2 APAC Epigenetics Drugs and Diagnostic Technologies Consumption by Type
6.3 APAC Epigenetics Drugs and Diagnostic Technologies Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Epigenetics Drugs and Diagnostic Technologies by Countries
  7.1.1 Europe Epigenetics Drugs and Diagnostic Technologies Consumption by Countries (2013-2018)
  7.1.2 Europe Epigenetics Drugs and Diagnostic Technologies Value by Countries (2013-2018)
7.2 Europe Epigenetics Drugs and Diagnostic Technologies Consumption by Type
7.3 Europe Epigenetics Drugs and Diagnostic Technologies Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies by Countries
  8.1.1 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Value by Countries (2013-2018)
8.2 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Consumption by Type
8.3 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Epigenetics Drugs and Diagnostic Technologies Distributors
10.3 Epigenetics Drugs and Diagnostic Technologies Customer

11 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET FORECAST

11.1 Global Epigenetics Drugs and Diagnostic Technologies Consumption Forecast (2018-2023)
11.2 Global Epigenetics Drugs and Diagnostic Technologies Forecast by Regions
  11.2.1 Global Epigenetics Drugs and Diagnostic Technologies Forecast by Regions (2018-2023)
  11.2.2 Global Epigenetics Drugs and Diagnostic Technologies Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Epigenetics Drugs and Diagnostic Technologies Forecast by Type
11.8 Global Epigenetics Drugs and Diagnostic Technologies Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Varlix Plc
  12.1.1 Company Details
  12.1.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.1.3 Varlix Plc Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Varlix Plc News
12.2 Topotarget
  12.2.1 Company Details
  12.2.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.2.3 Topotarget Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Topotarget News
12.3 Syndax Pharmaceuticals
  12.3.1 Company Details
  12.3.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.3.3 Syndax Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 Syndax Pharmaceuticals News
12.4 Spectrum Pharmaceuticals
  12.4.1 Company Details
  12.4.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.4.3 Spectrum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Spectrum Pharmaceuticals News
12.5 Promega
  12.5.1 Company Details
  12.5.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.5.3 Promega Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Promega News
12.6 Novartis
  12.6.1 Company Details
  12.6.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.6.3 Novartis Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Novartis News
12.7 Oncolys BioPharma
  12.7.1 Company Details
  12.7.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.7.3 Oncolys BioPharma Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Oncolys BioPharma News
12.8 MDxHealth
  12.8.1 Company Details
  12.8.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.8.3 MDxHealth Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 MDxHealth News
12.9 Merck
  12.9.1 Company Details
  12.9.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.9.3 Merck Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Merck News
12.10 Illumina
  12.10.1 Company Details
  12.10.2 Epigenetics Drugs and Diagnostic Technologies Product Offered
  12.10.3 Illumina Epigenetics Drugs and Diagnostic Technologies Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Illumina News
12.11 Epizyme
12.12 Forum Pharmaceuticals
12.13 EpiGentek
12.14 Chroma Therapeutics
12.15 Celleron Therapeutics
12.16 CellCentric
12.17 Astex Pharmaceuticals
12.18 Acetylon Pharmaceuticals
12.19 4SC AG
12.20 Eisai
12.21 Pharmacyclics

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Epigenetics Drugs and Diagnostic Technologies
Table Product Specifications of Epigenetics Drugs and Diagnostic Technologies
Figure Epigenetics Drugs and Diagnostic Technologies R